# Epidemiology of Surgical Site Infections: Incidence and Risk Factors at Jimma University Specialized and Comprehensive Hospital, Ethiopia

**Authors:** Mulatu Gashaw, Bikila Alemu, Andreas Wieser, Rahel Tamrat, Assefa Legesse Sisay, Kira Elsbernd, Rebecca Kisch, Gemechu Abera, Gersam Abera, Demisew Amenu Sori, Esayas Kebede Gudina, Arne Kroidl

PMC · DOI: 10.3390/antibiotics15020201 · Antibiotics · 2026-02-12

## TL;DR

This study examines surgical site infections at a hospital in Ethiopia, finding a high incidence and significant risk factors, including multidrug-resistant bacteria.

## Contribution

The study provides new insights into SSI incidence and risk factors in a tertiary hospital in Ethiopia, highlighting the prevalence of drug-resistant bacteria.

## Key findings

- The incidence of SSI was 9.2 per 1000 person-days, with most cases occurring during hospitalization.
- E. coli, Acinetobacter, and Klebsiella were the most common bacterial isolates, with over 67% of Gram-negative bacteria being ESBL producers.
- Age, gender, emergency surgery, and hospitalization duration were significant risk factors for SSI.

## Abstract

Background: Surgical site infections (SSIs) are healthcare-associated infections that can occur following surgical procedures, either at admission or within 30 days post-discharge. This study aimed to assess the incidence and associated risk factors for superficial SSI at a Tertiary Hospital in Ethiopia. Methods: A longitudinal study was conducted among patients undergoing surgery at Jimma University Specialized and Comprehensive Hospital (JUSCH) from 1 June to 30 September 2022. Pus, wound swab, or abscess samples were inoculated on Blood and MacConkey Agar for culture. Bacterial isolates were identified using MALDI-TOF, antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method, and the results were interpreted according to EUCAST 2022 breakpoints. Incidence rates, Kaplan–Meier analysis, extended Cox regression, and violin plots were utilized to analyze and present the findings. Results: Among 1205 participants, 629 (52.2%) were male, and the median age was 27 years (IQR: 16–40). The incidence of SSI was 9.2 per 1000 person-days. Most SSIs occurred during hospitalization (81.1%), and the remaining primarily developed within the first week post-discharge. The culture positivity rate was 72.7%, yielding 252 isolates comprising 36 bacterial species. The most frequently identified organisms were E. coli (22.2%), Acinetobacter (20.2%), and Klebsiella (14.7%). Over 67% of Gram-negative bacteria were ESBL producers. Age, gender, residence, hospital ward, surgery area, emergency surgery, longer hospitalization, and the number of staff attending the surgery were identified as important risk factors. Conclusions: This study revealed a high incidence of SSI during hospitalization, with significant proportion identified post-discharge. The high rates of multidrug-resistant Gram-negative pathogens underscore the urgent need for comprehensive infection prevention and control measures.

## Linked entities

- **Species:** Acinetobacter (taxon 469), Klebsiella (taxon 570)

## Full-text entities

- **Genes:** ESBL [NCBI Gene 13906541], SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}
- **Diseases:** AMR (MESH:C565965), pain (MESH:D010146), injury to (MESH:D014947), abscess (MESH:D000038), Gram (MESH:D016908), swelling (MESH:D004487), Diabetes mellitus (MESH:D003920), SSI (MESH:D013530), HIV (MESH:D015658), Hypertension (MESH:D006973), malnutrition (MESH:D044342), HAI (MESH:D003428), Infection (MESH:D007239), OMFS (MESH:D008446)
- **Chemicals:** carbapenems (MESH:D015780), CAZ (MESH:D002442), cefepime (MESH:D000077723), meropenem (MESH:D000077731), Methicillin (MESH:D008712), tobramycin (MESH:D014031), moxifloxacin (MESH:D000077266), gentamicin (MESH:D005839), piperacillin (MESH:D010878), FEP (MESH:D011138), cefoxitin (MESH:D002440), saline (MESH:D012965), ciprofloxacin (MESH:D002939), Agar (MESH:D000362), metronidazole (MESH:D008795), amoxicillin + clavulanic acid (MESH:D019980), sulfamethoxazole + trimethoprim (MESH:D015662), AMP (MESH:D000249), ampicillin (MESH:D000667), Steroid (MESH:D013256), beta-lactam (MESH:D047090), cefuroxime (MESH:D002444), cefalexin (MESH:D002506), CTX (-), cefotaxime (MESH:D002439), fluoroquinolones (MESH:D024841), amikacin (MESH:D000583), TM (MESH:D013932), cephalosporins (MESH:D002511), Ceftriaxone (MESH:D002443), piperacillin + tazobactam (MESH:D000077725)
- **Species:** Enterobacter asburiae (species) [taxon 61645], Providencia rettgeri (species) [taxon 587], Klebsiella variicola (species) [taxon 244366], Enterococcus (genus) [taxon 1350], Klebsiella (genus) [taxon 570], Aeromonas hydrophila (species) [taxon 644], Escherichia coli (E. coli, species) [taxon 562], Klebsiella pneumoniae (species) [taxon 573], Acinetobacter (genus) [taxon 469], Acinetobacter ursingii (species) [taxon 108980], Pseudomonas aeruginosa (species) [taxon 287], Citrobacter freundii (species) [taxon 546], Serratia marcescens (species) [taxon 615], Acinetobacter baumannii (species) [taxon 470], Morganella morganii (species) [taxon 582], Acinetobacter pittii (species) [taxon 48296], Staphylococcus haemolyticus (species) [taxon 1283], Ectopseudomonas mendocina (species) [taxon 300], Pseudomonas putida (species) [taxon 303], Staphylococcus cohnii (species) [taxon 29382], Corynebacterium striatum (species) [taxon 43770], Stenotrophomonas maltophilia (species) [taxon 40324], Klebsiella oxytoca (species) [taxon 571], Staphylococcus warneri (species) [taxon 1292], Enterobacter cloacae (species) [taxon 550], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606], Acinetobacter haemolyticus (species) [taxon 29430], Leclercia adecarboxylata (species) [taxon 83655], Staphylococcus pasteuri (species) [taxon 45972], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]
- **Mutations:** C for 16-18, D68C, C for 24-48
- **Cell lines:** ATCC-25922 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937284/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937284/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937284/full.md

---
Source: https://tomesphere.com/paper/PMC12937284